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ABSTRACT   
INTRODUCTION. Limited data exist on acceptability of candidate PrEP regimens among US 
women. We evaluated PrEP experiences, attitudes, and future use intentions among sexually 
active women who completed the US-based HIV Prevention Trials Network 069/ AIDS Clinical 
Trials Group 5305 study.  
METHODS. Women participated in the study between March 2013 and November 2015. We 
analyzed Computer Assisted Self Interview (CASI) surveys among 130 women and conducted 
in-depth interviews among a subset of 26 women from three sites. Interviews were conducted in 
mid/late-2015. 
RESULTS. Most women (57%) reported very good/excellent PrEP adherence on CASI, 
although 21% acknowledged over-reporting adherence at least some of the time. Commitment 
to preventing HIV infection, a sense of ownership of the study, and keeping pills stored in a 
visible location facilitated adherence. Adherence barriers included “simply forgetting” and being 
away from home. Most women interviewed did not intend to use PrEP in the future because of 
lack of perceived need due to their own (as opposed to their partners’) low risk behavior and 
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DISCUSSION. Improving HIV prevention options for US women will require access to affordable 
PrEP, as well as expanding women’s understanding of relationship- and community-level 
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INTRODUCTION  
Although the number of new HIV infections in the United States (US) has declined over the past 
decade, as of 2015, women constituted almost one quarter (24%) of all people living with HIV.1 
Until recently, HIV prevention strategies available to women at risk of heterosexual transmission 
were largely limited to approaches that required male partner cooperation (i.e., female or male 
condoms). Products that are safe, acceptable, discreet, and can be controlled by women are 
needed. Oral pre-exposure prophylaxis (PrEP) may be one such strategy. Randomized 
controlled-trials (RCTs) have demonstrated that daily oral tenofovir disoproxil 
fumarate/emtricitabine (TDF/FTC), when used correctly and consistently, is highly effective for 
preventing HIV infection among men and transgender women who have sex with men, 2-4 HIV 
seronegative partners in serodiscordant relationships, 5 and heterosexual men and women 6. 
However, two PrEP RCTs in sub-Saharan Africa that exclusively enrolled women7,8 failed to 
demonstrate efficacy, largely due to study drug non-adherence. A review of oral PrEP efficacy 
trials in women found that drug levels consistent with daily pill taking were associated with 
protection7
 
, suggesting that adherence is the critical factor influencing protective outcomes.  
Adherence, as well as attitudes and beliefs about PrEP, among men who have sex with men 
(MSM) in the US has received considerable attention in the literature.8-23 However, few studies 
have been published regarding attitudes towards use of PrEP among women who have 
accumulated real experiences taking candidate PrEP products. 24-27 Moreover, few PrEP 
demonstration projects among US women have been planned, 28
 
 leaving a substantial at-risk 
population in the US largely under represented. Despite PrEP’s promise as an HIV prevention 
tool for US women, the lack of data on product acceptability and adherence in this population 
(especially in the setting of inconsistent adherence demonstrated in international clinical trials) 
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In response to this paucity of data, we collected quantitative and qualitative data from women 
participating in HIV Prevention Trials Network (HPTN) 069/AIDS Clinical Trials Group (ACTG) 
5305 study29
 
 to better understand reasons for adherence and/or non-adherence to study drug, 
attitudes towards PrEP and intentions to use PrEP after the end of the study. Given the few 
PrEP trials involving US women and demonstration projects seeking to involve them, the results 
of this study may help develop approaches for supporting adherence in the rollout of current and 
future PrEP technologies. 
METHODS 
Clinical Trial  
HPTN 069/ ACTG 5305 was a prospective, randomized, double-blinded, multisite, safety and 
tolerability study of 4 antiretroviral regimens for HIV PrEP: (1) maraviroc (MVC) alone; (2) MVC 
+ emtricitabine (FTC); (3) MVC + tenofovir (TDF); (4) TDF + FTC (control) conducted with 
women in the US between March 2013 and November 2015. 29 As described in detail in the 
presentation of primary outcomes, 29 study regimens consisted of 3 pills once-daily: MVC 300 
mg, FTC 200 mg, TDF 300 mg, with matching placebos. HIV-seronegative women who reported 
a history of condomless vaginal or anal intercourse with >1 HIV-seropositive male partner or 
man of unknown sero-status within 90 days, and had adequate safety laboratory parameters 
were enrolled at 12 US based study sites (Baltimore, MD; Boston, MA; Chapel Hill, NC; 
Cleveland, OH; Los Angeles, CA; Newark, NJ; New York City, NY; Philadelphia, PA; Pittsburgh, 
PA; San Juan, PR; Seattle, WA; and Washington, DC). Participants received randomized study 
regimens for 48 weeks with follow-up visits at weeks 2, 4, and 8, and then every 8 weeks 
through week 48. At each study visit, interval history, physical exam, safety laboratories, blood 
plasma for drug levels, HIV testing and adherence counseling were performed at all study visits. 
Electronic drug monitoring (EDM) was used throughout the trial via a single pillbox (WisepillTM
 
) 
containing the three study medications.  
The study protocol and the procedures for the qualitative sub-study were approved by 
institutional review boards at the local institutions affiliated with each study site. Written informed 
consent was obtained from all participants prior to conduct of any study-related activities. 
 
Survey Data.  
Detailed behavioral risk assessments and HIV risk perception were assessed via Computer 
Assisted Self Interview (CASI) at baseline and serially (every 8 weeks). Attitudes toward study 
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conclusion were measured at Week 48. Adherence related facilitators and barriers were 
identified by women using a list where they could select all that applied.  
 
We reviewed CASI data specific to beliefs, attitudes and adherence among the 130 women who 
were on study drug at week 48. As reported in the presentation of the primary outcomes for 
women in the parent study (HPTN069/ACTG5305)29
 
, of 188 women enrolled, 160 (85%) 
completed study follow-up and of them, 30 participants had permanently discontinued the study 
regimen prior to week 48. Thus, we focused on CASI data from women with recent experiences 
with the study drugs (N=130 women on study medication). Although the study used biological 
markers of adherence in a subset of women, the current evaluation focused on self-report data 
and did not seek to distinguish between those with and without detectable drug at week 48.  
Analyses. Data analysis was performed for all enrolled women who completed the parent trial 
and had not discontinued their assigned study regimen. CASI data were analyzed using SAS 
9.4 (SAS Institute, Cary, NC). Descriptive statistics were performed to provide a demographic 
profile of study participants and summarize survey responses. 
 
In-Depth Interviews (IDIs)  
A sub-set of twenty-six women from three sites (New Jersey, New York and North Carolina) 
were interviewed within 2-weeks of study completion (week 48). Convenience sampling was 
used, as the qualitative protocol was adopted late in the parent study and there was no 
opportunity to randomly select from the small pool of women who remained in the study. Site 
staff invited study participants to join the qualitative sub-study as they completed their final study 
assessments. Interviews were conducted with a total of 26 women, which included 23 who were 
on study-drug at the end of the study and 3 who had discontinued prior to study end. In contrast 
to CASI collected data, we retained the 3 who had discontinued study-drug in the interview sub-
set of women because interviewers could provide the opportunity to probe and unpack 
experiences with study drug over the course of the study.  
 
Interview domains in the structured interview guide included experiences using a candidate 
PrEP regimen, attitudes towards the study drug, factors contributing to product adherence or 
non-adherence, HIV risk perception, and intention to use PrEP after study completion. 
Interviews were conducted by a trained interviewer identified at each site and lasted an average 
of 1.5 hours. Participants received $75 as compensation for their time and were reimbursed for 
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Jersey Medical School (NJ), Weill Cornell Medicine (NY) and the University of North Carolina at 
Chapel Hill (NC). 
 
Analyses. Interviews were transcribed, coded and analyzed in Dedoose 7.0.23 (SocioCultural 
Research Consultants, Los Angeles, CA) using a thematic framework analysis approach 30-32
 
. 
Five trained analysts reviewed the transcribed interviews and applied coding “frames” based on 
the in-depth interview guide. Each frame was iteratively reviewed by several members of the 
coding team in order to identify and document key themes across the interview. Through this 
process a codebook was developed with detailed and nuanced definitions of key themes, 
supporting themes, and example quotes. Thematic codes were applied to transcripts using 
Dedoose. Inter-coder agreement was assessed at various points in the analysis process. 
Coding discrepancies were discussed by the analysis team, the codebook revised accordingly, 
and recoding performed when necessary to ensure consistent application of codes. To identify 
the most salient themes, code frequency reports and coded text reports were generated. 
RESULTS 
Participant Char acteristics  (Table 1)  
As detailed in Table 1, the median age of female respondents who completed the parent trial on 
their assigned drug regimen (N=130) was 39 years (range: 18-61). Most were not married 
(90%), had completed high school but less than a 4-year college degree (82%), and were 
unemployed (59%). Almost three-quarters of participants (74%) identified as non-White and 
13% self-reported Hispanic/Latina ethnicity. At baseline, women reported an average of two 
sexual partners (SD: 9.0) in the past month and one partner with whom a condom was not used 
(SD: 2). Women completing the trial on study drug were largely comparable to those who 
discontinued early, with the exception of being older (39 vs 32 years of age). Women in the 
interview subset did not significantly differ from the full sample of women in demography or 
behavioral characteristics.  
 
Computer Assisted Self -Interview (CASI)  
Self-reported Drug Adherence 
Participants reported generally high adherence at week 48. As presented in Table 2, more than 
three-quarters of women reported taking study drug most of the time (35%) or always (44%) in 
the past thirty days. Most women similarly reported their ability to take daily study medications 
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reported their adherence to study team members; 21% reported over-estimating their actual 
adherence intentionally some to all of the time.  
 
Barriers and Facilitators To Product Adherence 
The most commonly cited challenges to adherence (Table 3) were “forgetting” (45%), being 
away from home (39%), and not having pills available when they were scheduled to be taken 
(22%). Few participants reported HIV-stigma (4%), concern about disclosing participation in the 
study (4%) or concerns about side-effects (8%).  
 
Respondents identified commitment to preventing HIV infection (63%), a sense of “ownership” 
of the study (38%), and making sure pills are available (28%) and stored in a location that was 
easily visible to them (34%) as factors that made adherence easier (Table 3). About a third of 
participants integrated pill-taking into existing routines (31%), developed reminder strategies 
(23%), or kept track of dosing on their pill boxes (13%). Twenty-six percent of women reported 
concern about HIV acquisition as facilitating adherence. 
 
Attitudes Towards PrEP  
Women estimated the efficacy of the study drugs (how good the study drugs were at preventing 
HIV infection), on average, to be 69% out of 100%. Most participants had an overall positive 
opinion of PrEP. As presented in Table 4, over 75% would recommend PrEP to others, and 
most (60%) believed PrEP would be good for “anyone.”  
 
Almost half of participants (48%) reported an increase in HIV preventive behavior while on study 
(“Since getting the study pills, I do more to protect myself against HIV than I did before”). In 
response to items asking about which prevention modalities women felt they had the most 
“control” over, half of women (50%) reported feeling they had more control over a partners’ 
condom use than daily PrEP; more than a quarter of women (29%) perceived an equal amount 
of control and only about 20% reported they felt more personal control over PrEP use.  
 
In-Depth Interviews (IDIs , N=26) 
Experience Using Study Product 
Two main themes were identified concerning women’s experiences using study products: (1) 
unrealized anticipated side-effects and (2) appreciation of the benefits of participating in a study. 
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first weeks of the study. A number of participants also described the importance of education 
and counseling by study staff in tempering their concerns about possible side-effects 
 
Participant: I had a little bit of diarrhea. That’s it. No vomiting, no nausea, none of that. 
Just one day total. So it really wasn’t bothersome at all in terms of, “I don’t want to take 
this medicine because of it.” 
 
Participant: At first, the study nurse said, “You might get some side-effects,” and I was 
like, “Wait a minute. What am I getting myself into?” and then, once I started taking it 
and a week went by, I said, “Oh, okay, I see now”, and I would take my medicine every 
day, every day. 
Interviewer: So you were a little nervous at first. 
Participant: At first, yeah, because I didn't know how, because she said some people, it 
didn't make them feel right. I said, "Well, I wonder how it's going to affect me?". She 
said, "It might not affect you the way it affect them," so I started taking it, and I was fine. I 
was okay. 
 
Participants also described experience with the study that were appreciated and described as 
beneficial, including regular HIV testing and health monitoring.  
 
Participant: I liked the fact that I got checked for – I got my blood checked and 
everything, HIV tested. 
 
 Participant: I liked the fact that they gave you condoms. And even though they don’t – I 
wouldn’t – I didn’t want to get paid for it but they was like “Well we pay you anyway.” I 
was like “Ok. That’s fine.” I get the money, the bus tickets and then like I get the 
information. I get schooled on some things. I really like the fact that I could learn from it. 
 
Barriers and Facilitators To Product Adherence 
Four themes concerning barriers and facilitators to study drug adherence were identified (Table 
5). Three themes described barriers to study product adherence: (1) the impact of competing 
demands (e.g., family, employment, unrelated health issues, unexpected events); (2) lack of 
established routine; and (3) believing one should not dose if the ‘prescribed’ dose time was 
missed. Participants did not describe any concerns about side-effects or perceived HIV-related 
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One overarching theme was identified as facilitating adherence: consciously building adherence 
habits (e.g., using cell phone alerts, keeping pills visible, engaging their social network to help 
with reminders). In addition, almost all of the women who were interviewed valued the care they 
received as research participants and expressed a desire to contribute to HIV prevention 
research, although participants did not link these factors to study drug adherence. 
 
Future Use Intentions  
Of the twenty-six women interviewed, only nine expressed clear intentions of using PrEP after 
the study ended. The most commonly cited reasons for not planning to use PrEP were (1) low 
perceived HIV risk and (2) uncertainty about PrEP access and efficacy (Table 6).  
 
Women perceived themselves to be at low risk of HIV acquisition, citing their own monogamy, 
their partner’s low risk of acquiring or having HIV, and condom use. A few women reported 
discontinuing sexual partnerships during the course of trial, and did not feel that they would 
need PrEP until they were once again sexually active. Valuation of risk appeared largely 
focused on women’s own (versus partner) behavior, with being in a monogamous relationship 
often noted as evidence for no HIV risk.  
 
Women also expressed uncertainty about where to access PrEP and whether it would be 
covered by insurance; some participants were unaware that oral PrEP with TDF/FTC was FDA- 
approved for at-risk women in the US. Women were also unsure how PrEP would fit into their 
current HIV-prevention strategies, whether it would be efficacious enough to replace condoms, 




Although most new HIV infections in the US are among men, more than 7,000 women received 
an HIV diagnosis in 2016.1 We used mixed methods (CASI and in-depth interviews) to explore 
acceptability of, adherence to, and intentions concerning future use of PrEP among US women 
who completed a 48 week Phase II prospective, randomized, double-blinded, multisite, safety 
and tolerability study of four candidate PrEP regimens comprised of combinations of TDF, FTC, 
and MVC. Women found the study regimens acceptable, but among those interviewed a lack of 
perceived risk or need and concerns about affordable access limited enthusiasm for using PrEP 
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Women reported high levels of adherence, with most reporting taking their study drugs most or 
all of the time during the previous month; however, nearly a quarter of women acknowledged 
over-reporting the proportion of study medications they had taken at times. Previous studies 
have linked intentional non-adherence and over-reporting adherence to study teams as related 
to concerns about safety and side-effects 33-37
 
; however, few women in our study cited side-
effects as barriers to adherence or discussed safety concerns in interviews. Participants 
discussed initial apprehension about side effects that were never realized, which may have 
decreased concerns about safety over time.  
Lapses in drug adherence were often explained as unintentional and due to a lack of 
established routines, reminder tools, and competing demands. Several women also reported the 
(erroneous) belief that a dose could or should not be taken if the exact “prescribed” dose time 
was missed. In CASI and interviews, facilitators for taking pills included developing habits, such 
as keeping pills visible, and a commitment to HIV research and to the study. The impact on 
adherence of developing habits and using reminder tools is well described in the ART (and 
other) adherence literature 38-41
 
, and further underscored by our findings. These results highlight 
the importance of verifying patients’ understanding about the timing of medications and what to 
do when doses are inadvertently missed or taken late.  
Women had generally positive impressions of PrEP after participating in the study and believed 
PrEP would be a useful HIV prevention tool and “good for anyone,” with a majority indicating 
they would recommend it to others. However, some women in the interviews expressed 
uncertainty about using PrEP in the future because they were unsure about how PrEP would fit 
into their current HIV-prevention strategies and whether it would be accessible through 
insurance. In fact, several women seemed unaware that an FDA-approved PrEP regimen was 
available to at-risk women in the US. Intentions for PrEP uptake may have been higher if the 
study actively transitioned participants to PrEP prescribers in the local area. But the major 
reason for women’s relative lack of interest in using PrEP after the study was their perception 
that they were not at risk for HIV acquisition. Discourse concerning participants’ valuation of risk 
was focused almost exclusively on the participant’s behavior – with little attention to the 
influence of partner characteristics and community HIV infection rates. Although women in our 
study may have accurately assessed their likelihood of acquiring HIV, their assessments could 
also have missed important external factors that elevated their risk, such as community-level 
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(condomless sex, number of partners) behaviors, however future research should carefully 
consider associations between reported behavior and valuation of HIV-risk for women 
specifically. A more holistic discourse about HIV risk and risk perception that includes partner, 
community, and structural influences may be particularly important for women’s uptake of PrEP 
in communities that are highly impacted by HIV. Although our study was conducted in the US, 
this recommendation may generalize widely; women’s unique vulnerabilities to HIV are 
worldwide42
 
 and campaigns that focus on individual risk factors may promote an underestimate 
of HIV risk for women.  
Surprisingly, women did not appear to consider PrEP as a prevention strategy that was more 
under their control than condoms. Because condom use often requires women to negotiate with 
partners or otherwise rely on partner initiated behaviors and PrEP is self-directed and can be 
administered without partner awareness43
 
, we had anticipated that most women would rate 
PrEP as more in their immediate control than condom use. The most commonly selected 
response to this item was perceiving more control over condom use. This may have been 
influenced by the study context- which involved taking a study drug under evaluation; where as 
they can visually see a condom being used and are confident in its function, they cannot see the 
study drug “working” and do not know if it is actually effective. Additionally, women were 
counseled on use of condoms throughout the study, with more than half reported that 
participation in the study increased their use of prevention strategies over time. Thus, this 
finding should be re-examined in the context of open-label (known to be effective), easily 
accessible, PrEP projects. 
Findings should also be interpreted in light of several limitations. First, only a small number of 
study participants at three sites were asked to participate in in-depth interviews, thus may not be 
representative of the women in the overall study. Second, HPTN 069/ACTG 5305 trial 
participants were healthy volunteers in a blinded trial; women not engaging in research may 
differ from those who do in concerns about safety and challenges with intentional non-
adherence. Additionally, while eligibility criteria required participants to be at-risk for HIV (i.e., 
condomless vaginal or anal intercourse with ≥1 HIV-infected or unknown-serostatus man within 
90 days of enrollment) they were not necessarily at high-risk for HIV infection. Finally, study-
drug adherence and related attitudes towards the drug and the regimen may dramatically differ 
from adherence and attitudes towards drugs known to be effective and widely available outside 
of a study context. Study participants completed interviews in late 2015. Efforts to increase 
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that time, although PrEP uptake remains generally low. Nonetheless, women in our study may 
differ in terms of PrEP knowledge, awareness and attitudes from more contemporary samples.44
 
 
Strengths of this study include a study population that is racially and ethnically similar to that of 
women living with HIV in the United States, with significant representation from Black and 
Hispanic women. Additionally, study sites were broadly representative of US major cities and 
geographically reflect US regions most affected by the HIV epidemic. 
 
CONCLUSION 
Women’s valuation of their personal risk for HIV infection will be critical to PrEP’s success as an 
HIV prevention strategy for women. Building women’s demand for PrEP may be challenged by 
their personal risk assessments in settings where individual-level risk factors appear minimal but 
contextual and partner-level factors confer elevated risk for HIV. More holistic thinking about 
women’s HIV risk will be needed to maximize the effectiveness of PrEP as an HIV prevention 
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Table 1: Characteristics Among Women Participants in HPTN069/ACTG5305 who 
Completed Week 48 on Study Regimen  
 All  
N=130 
Age  
Median (range) 39 (18,61) 
Marital Status   
Married/Civil Union 13 (10%) 
Dating, living with partner 27 (21%) 
Dating, not Living with partner 15 (12%) 
Single/Divorced/Widowed 73 (56%) 
Other 2 (2%) 
Employment Status  30 (23%) 















Adherence, Acceptability and Future Use Intentions 
This article is protected by copyright. All rights reserved 
Part-time Employment 76 (59%) 
Not Employed  
Education   
< High School 18 (14%) 
High School Graduate  46 (35%) 
Vocational/Technical School 8 (6%) 
Some College or Two Year Degree 34 (26%) 
Finished College or Graduate School 24 (19%) 
Ethnicity -Latino   
Hispanic/Latino 17 (13%) 
Race  1 
Black or African American 83 (64%) 
White 34 (26%) 
Other 13 (10%) 
Sexual Behavior at Baseline  
Vaginal sex with a man in the past month 106 (82%) 
Mean number of sex partners in the past month (SD) 2 (9) 
Mean number of sex partners in the past month with 
whom no condom was used (SD) 
1 (2) 
Sexual Behavior at Week 48  
Vaginal sex with a man in the past month 98 (75%) 
Mean number of sex partners in the past month (SD) 2 (3) 
Mean number of sex partners in the past month with 
whom no condom was used (SD) 
1 (1) 
1 
Table 2.  Adherence to PrEP Study Drugs Reported by Computer Assisted Self -Interview 
at Week 48  
Participants self-reported and were able to select more than one category; SD Standard 
Deviation 
 N=130 
Adherence in past 30 days  
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Most of the time 46 (35%) 
Half of the time 11 (7%) 
Some of the time 8 (6%) 
None of the time 3 (2%) 
Missing 5 (4%) 
Frequency of adherence over -
reporting  
Never 98 (75%) 
Some of the time 17 (13%) 
Most of the time 7 (5%) 
All of the time 4 (3%) 
Declined to answer 4 (3%) 
Ability to take study meds every day  
Excellent 51 (39%) 
Very good 23 (18%) 
Good 23 (18%) 
Fair 21 (16%) 
Poor 4 (3%) 
Very poor 2 (2%) 
Declined to answer 1 (1%) 




Table 3. Barriers and Facilitators for Taking Prep During HPTN069/ACTG5305 Study 
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 N= 130 
 1 
I did not have pills with me when I was supposed to take them 28 (22%) 
I got confused by the instructions for when to take the pill 1 (1%) 
I ran out of pills 2 (2%) 
I wasn't able to tell when sex was going to happen 3 (2%) 
I forgot 59 (45%) 
I was worried about others thinking I have HIV because they 
saw me taking the pill 
5 (4%) 
I was worried about others knowing I was in the study 
because they saw me taking the pill 
5 (4%) 
I did not have a private place to take the pill 2 (2%) 
I was worried about or experiencing side effects 10 (8%) 
I was away from home 50 (39%) 
Declined to answer 17 (13%) 
  
I felt committed to finding a way to prevent HIV 82 (63%) 
I felt like it is my study 50(38%) 
I kept pills available/with me when I would need them 36 (28%) 
I worked pill-taking into something I do anyway 41 (32%) 
I got better/am good at planning for when I will and will not 
have sex 
14 (11%) 
I used a reminder strategy 30 (23%) 
I (or the site) marked the days of the week on my pill case 17 (13%) 
I kept pills out where I could see them as a reminder 44 (34%) 
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I have had helpful conversations with study team members 16 (12%) 
I have had helpful conversations with other participants 4 (3%) 
I am scared of getting HIV 34 (26%) 
Other 8 (6%) 
Declined to answer 8 (5%) 
1
Table 4. Attitudes Toward Taking Prep During HPTN069/ACTG5305 Reported By Women 
Participants  
Participants could select more than one response  
  
 N=130 
How good are study meds at preventing HIV (0 -100%)  
     Mean (SD) 69 (28) 
Would you recommend the PrEP medications used in this   
study to others  
 
Yes  98 (76%) 
No  1 (1%) 
Not sure  30 (23%) 
Declined to answer 1 (1%) 
Who would this kind of prevention approach be good for   
Anyone 78 (60%) 
Most people 32 (25%) 
Some people 12 (9%) 
Only very few people 6 (5%) 
Declined to answer 2 (1%) 
Since getting the study pills I do more to protect myself 
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Agree 60 (48%) 
Somewhat agree 14 (11%) 
Neither agree nor disagree 19(15%) 
Somewhat disagree 4 (3%) 
Disagree 27 (22%) 
Declined to answer 1 (1%) 
Which prevention strategies do you feel you have more 
personal control over  
 
Condoms (male or female) 65 (51%) 
Daily PrEP 25 (19%) 
Neither, same amount of control using either condoms or 
PrEP 
37 (29%) 
Declined to answer 3 (2%) 
 
 
Table 5. Barriers and Facilitators To Product Adherence, and Illustrative Quotes  
Theme Quotes  
Barriers  
Competing Demands  
Discussion that supported this theme 
centered around obligations that took 
priority over participation in the research 
study, including: family needs, 
employment, emergencies, and other 
unplanned life events. 
Participant: Actually, I was actually stressed 
because my 18-year-old was locked up. So, I was 
running back and forth to court to see what they 
were going to do with him. But it took two months. 
So, out of the two months, I was just stressed 
because I was like, “I could lose my Section 8. I 
could be homeless.” And it was like I wasn't really 
focusing on this box right here [WISEPILL] because 
now I've got to fuck with my livelihood. You get what 
I'm saying?  
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I had missed my cycle…Once I missed my cycle, I 
already knew something wasn't right.  So I was like, 
"Okay, I gotta be pregnant."  So I stopped.  And the 
reason why I stopped, because I really didn't know if 
I was going to keep my baby or terminate my baby.  
 
Participant: I got hit by a van − during this study, 
and I didn't take my medicine because I was in the 
hospital, and Susana [study nurse]  was like, 
"What's going on?" The phone was going and 
everything, so once I got out of the hospital, I came 
over here and let them know what happened, and I 
didn't take the medicine for, like, five days. 
 
Lack of Established Routine  
Women discussed a lack of established 
routine, including changes in daily 
schedule, employment-related events and 
long term travel or moving. Although 
these events often resulted in only one or 
two missed pills, some women reported 
that unanticipated events caused them to 
miss follow-up clinic visits, leading to 
longer periods of non-adherence.   
Participant: At the beginning when I had the little 
box [WISEPILL] with me. ... But I think it’s because I 
usually look at it and it was just like a box. So I need 
to remember the pills was in there — I don’t know. 
But at the beginning was real hard for me to stay on 
track with taking the pills. But once the months went 
by and I got used to it, like, it was routine.” 
 
Participant: [I] just totally forgot because I'm not 
used to it…. I missed Tuesday, I missed 
Wednesday. That's when I said you know what, I've 
got to think of another way because I can't 
remember. I have a problem with memory so I need 
it to be in my sight. When I wake up, [yawns], 




Not Dosing if Dose Time was Missed  
Some women reported not dosing when 
Participant: Oh shit. I can't take them now it's after 
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they missed their specific dose time, 
suggesting that some did not understand 




Consciously Building Adherence 
Habits  
Discussion that supported this theme 
centered around developing new routines 
and pill-taking reminders.  This included 
using technology (cell phones, alarm 
clocks), keeping pills in a visible location,  
as well as developing routines for pill –
taking individually or in conjunction with 
others.  
Participant: But you could set your timer on the 
phone, but when you're not used to taking pills, it's 
kinda hard.  You forget.  But once you start being in 
the study for a long time, you'll start taking them 
more regularly. 
 
Participant: I knew that I had to take them. So, 
when I get up I eat and I'll just take the pills– I knew 
I had to take it because I was – I'm in the research, 
so I knew I had to take it. So, I'd just wake up in the 
morning and eat and just take them.  
 
Participant: Yeah, and sometimes my fiancé said, 
“Did you take your medicine this morning?”  and I 
was like, "Yes, I took it," because he has diabetes 
so he takes his medicine, so I would take mine. 
He'd be like, "Take your medicine," and I was like, 
“I'm taking it,” so he would take his medicine and I 
would take mine. 
 
 
Table 6. Themes About PrEP Future Use Intentions, and Illustrative Quotes  
Theme Quotes  
Low perceived HIV risk  
 
Participant: I don't need them no more…I only 
have one partner and I've been with my partner for 
four years, so – it's a female. … When I was 
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Participant: Right now, no, just because I have one 
partner and he – I don't know. Maybe if I switched 
my life around a little bit but right now I don't think 
[so] just because I don't feel like my risk is very 
high. 
 
Participant: Yeah, I'd use it. I'm [in] an intimately, 
good relationship now, so I don’t really foresee that 
changing.  But, you know, you never know.  And 
you never really know your partner's full history, I 
guess, unless you, you know, make them give them 
a medical report or something, so I'm pretty 
confident about the one I have now, but, you know, 
what could happen later you just don’t – you can't 
predict. 
 
Uncertainty about PrEP Access and 
Efficacy  
Interviewer: Mm-hmm.  So it's [PrEP] something 
that you would use.  So do you think you would use 
it by itself or part of another prevention… plan, so to 
speak? 
Participant: I think it would be the primary one.  But 
I can also see, you know, using condoms. 
Interviewer: Okay.  Okay.  All right.  And any idea 
as to where you might could get PrEP today? 
Participant: Well, I'm not sure if you can get it as 
PrEP…I don’t think it's been approved for that yet.  
But hopefully, you know, after this it will be. 
 
Participant: That's a good question. I don't know. I 
… I don't think that I'm in like a risk bad enough for 
me to take it. And I'd also have to – I guess we 
didn't talk about – I never mentioned cost. I guess 
that would be a really good –  
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know where you would go and get it, like your 
provider or – how much it costs or anything.  
Participant: No, I wouldn't even know how to start. 
So I guess that's also the facilitation, the question 
before, talking to your doctor about it, talking to your 
pharmacy about it, and then just having the money 
to actually do it.  
 
Participant: Yeah, as long as I could – my 
insurance would – but I know condoms the best way 
to prevent HIV.  But it wouldn't be bad to take that 
pill. 
Interviewer: So if your insurance covered it, you 
think it would be something you would look into? 
Participant: Yeah. 




Interviewer: Okay.  Are you planning to use PrEP 
at some point in the near future? 
Participant: No.  [Laughter] 
Interviewer: Why wouldn't you use PrEP? 
Participant: I mean I wouldn't even know how to 
get it… 
Interviewer: Like where to go, where to get it from? 
Participant: Yeah. Yeah. No idea. 
 
Participant: I think I would trust it.  I mean 
depending on how the outcomes look and how 
effective it is.  I mean I think that alone could be 
effective enough for preventing HIV if it's 
comparable to condoms or things like that.  I mean 
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know, some way to prevent other STDs.  So it 
would be in combination with other things too.  
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